ESMO 2016: Congress Highlights for Journalists

With the ESMO 2016 just around the corner, we've selected some sessions of interest for journalists attending the congress

The full ESMO 2016 Press Programme will be available mid-September.

80 late-breaking abstracts submitted

Top submissions are in the fields of colorectal and gastrointestinal cancers, non-small-cell lung cancer, genitourinary tumours and immunotherapy.

Keynote lectures

These must-attend sessions will give delegates the full picture regarding the evolution of cancer research and patient care, reaching beyond individual disease types to offer thought-provoking interdisciplinary discussion including:

  • The development of checkpoint inhibitors by Jim Allison, Saturday, 8 October, 13:00
  • The art of the possible: Bridging the gap between genomics and patient care? by Emile Voest, Sunday, 9 October, 13:00
  • The patient journey: Is cancer cure around the corner? by Jean-Charles Soria, Monday, 10 October, 13:00

Onco-immunology

A fully-dedicated track with more than 100 abstracts submitted, including hands-on educational sessions for practitioners, with a focus on patient selection and side-effect management.

Other programme highlights include:

  • Record number of abstracts submitted under the Biomarkers topic, highlighting the importance of patient selection in treatment efficacy from the early phases of drug development to the bedside.
  • Spotlight on resistance to therapy, the use of mouse models to help develop better targeted therapies and adapting clinical trials to tumour biology.
  • The latest on BRCA testing in ovarian cancer and triple-negative breast cancer.
  • Challenges and promises in the treatment of tumours of the central nervous system.
  • How to provide patients with precision medicine in the clinic – interdisciplinary patient cases to translate theory into reality.
  • A “Drugs you will be using in 2020” special symposium to share a vision of what to expect in the years ahead.
  • Cancer prevention and screening including evidence-based prevention approaches.
  • Public policy: sessions focusing on the most important public policy issues including the equitable delivery of anti-cancer drugs, the registration and use of Big Data and individual molecular profiles, and different approaches to qualify clinical benefit in oncology.